American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 192-197 , January 2010

Crystal-Induced Kidney Disease in 2 Kidney Transplant Recipients

  • Ravi Parasuraman, MD

      Affiliations

    • Division of Nephrology and Transplantation, William Beaumont Hospital, Royal Oak, MI
    • Corresponding Author InformationAddress correspondence to Ravi Parasuraman, MD, Kidney Transplant Outreach Program, Division of Nephrology and Transplantation, William Beaumont Hospital, Royal Oak, MI 48703
  • ,
  • K.K. Venkat, MD

      Affiliations

    • Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI

Received 19 December 2008 ,Accepted 14 August 2009.

References 

  1. Coe F, Parks JH. Defenses of an unstable compromise: crystallization inhibitors and the kidney's role in mineral regulation. Kidney Int. 1990;38(4):625–631
  2. Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol. 1996;270(4 pt 2):F604–F613
  3. Heher EC, Thier SO, Rennke H, Humphreys BD. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol. 2008;3(5):1494–1503
  4. Rose BD. Pathophysiology of Renal Disease. 2nd ed.. New York, NY: McGraw-Hill; 1987;http://www.loc.gov/catdir/description/mh031/86033710.htmlAccessed July 27, 2009
  5. Kjellstrand CM, Cambell DC, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133(3):349–359
  6. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–465
  7. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy an update. Expert Opin Drug Saf. 2008;7(2):147–158
  8. Seshan SV. Renal Disease: Classification and Atlas of Tubulo-Intestitial and Vascular Diseases. Baltimore, MD: Williams & Wilkins; 1999;
  9. Truong LD, Yakupoglu U, Feig D, et al. Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications. Am J Transplant. 2004;4(8):1338–1344
  10. Rathi S, Kern W, Lau K. Vitamin C-induced hyperoxaluria causing reversible tubulointerstitial nephritis and chronic renal failure: a case report. J Med Case Rep. 2007;1:155
  11. Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med. 1994;24(4):410–411
  12. Alkhunaizi AM, Chan L. Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure. J Am Soc Nephrol. 1996;7(11):2320–2326
  13. Mashour S, Turner JF, Merrell R. Acute renal failure: oxalosis, and vitamin C supplementation: a case report and review of the literature. Chest. 2000;118(2):561–563
  14. Gabardi S, Munz K, Ulbricht C. A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol. 2007;2(4):757–765
  15. Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr. 2005;135(7):1673–1677
  16. Gossel TA, Bricker DJ. Principles of Clinical Toxicology. In: New York: Raven Press Ltd; 1994;p. 415
  17. Laroche M, Boyer JF. Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine. 2005;72(5):376–381
  18. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’?. Kidney Int. 2006;70(8):1486–1494
  19. Ettinger DS, Harker WG, Gerry HW, Sanders RC, Saral R. Hyperphosphatemia, hypocalcemia, and transient renal failure (Results of cytotoxic treatment of acute lymphoblastic leukemia). JAMA. 1978;239(23):2472–2474
  20. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med. 1991;325(26):1843–1848
  21. Science background paper: acute phosphate nephropathy and renal failure associated with the use of oral sodium phosphate bowel cleansing product. www.fda.gov/Drugs/DrugSafety/…/ucm161581.htmAccessed July 27, 2009
  22. Lien YH. Is bowel preparation before colonoscopy a risky business for the kidney?. www.nature.com/clinicalpractice/nephAccessed July 27, 2009
  23. Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med. 2003;349(10):1006–1007
  24. Orias M, Mahnensmith RL, Perazella MA. Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol. 1999;19(1):60–63
  25. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16(11):3389–3396
  26. Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol. 2004;35(6):675–684
  27. Heher EC, Rennke HG, Humphreys BD. Nephrocalcinosis, oral sodium phosphate solution, and phosphate nephropathy. Nephrol Rounds. 2007;5(2):1–6http://www.nephrologyrounds.org/crus/nephUS_0207.pdfAccessed July 27, 2009
  28. Keeffe EB. Colonoscopy preps: what's best?. Gastrointest Endosc. 1996;43(5):524–528
  29. DiPalma JA, Brady CE. Colon cleansing for diagnostic and surgical procedures: polyethylene glycol-electrolyte lavage solution. Am J Gastroenterol. 1989;84(9):1008–1016
  30. Schwetz BA. From the Food and Drug Administration. JAMA. 2001;286(21):2660
  31. Murphy-Gutekunst L. Hidden phosphorus in popular beverages: part 1. J Ren Nutr. 2005;15(2):e1–e6
  32. Saldana TM, Basso O, Darden R, Sandler DP. Carbonated beverages and chronic kidney disease. Epidemiology. 2007;18(4):501–506
  33. Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45(8):911–916
  34. Calvo MS. Dietary considerations to prevent loss of bone and renal function. Nutrition. 2000;16(7-8):564–566

 Originally published online as doi:10.1053/j.ajkd.2009.08.012 on November 2, 2009.

PII: S0272-6386(09)01144-5

doi: 10.1053/j.ajkd.2009.08.012

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 192-197 , January 2010